UPDATE 1-Sernova diabetes control device shows promise in pigs

* Pre-clinical study shows safety and efficacy of device

* Co says no adverse events reported

July 12 (BestGrowthStock) – Canada’s Sernova Corp (SVA.V: ) said its
experimental glucose-control device showed safety and efficacy
in a pre-clinical study in pigs that were made diabetic.

The pigs treated with the company’s Cell Pouch System,
which is implanted under the skin, achieved long-term glucose
normalization throughout the course of the study, Sernova said
in a statement.

The animal’s own islets, or insulin-producing tissues, were
isolated from the pancreas and transplanted into the device
that helps to provide a natural environment for the survival
and function of therapeutic cells.

The study suggested the device could achieve glucose
control with significantly fewer islets than normally required
and reduce side-effects associated with the current
standard-of-care where islets are directly injected into the
portal vein of the liver, the company said.

Shares of the company closed at 11 Canadian cents Friday on
the Toronto Venture Exchange.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by
Gopakumar Warrier)

UPDATE 1-Sernova diabetes control device shows promise in pigs